drugset / Trial / NCT04572776
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a Phase 3 study to assess the safety and efficacy of a single epidural administration of Resiniferatoxin versus standard of care for the treatment of intractable pain associated with cancer.
Timeline
- Start
- 2020-12
- Primary completion
- 2023-03
- Completion
- 2023-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resiniferatoxin | Other / unclassified | 25 ug | Other |